Actinium Pharmaceuticals (ATNM) Stock Price Down 12.2%

Shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) were down 12.2% during trading on Friday . The stock traded as low as $0.36 and last traded at $0.36. Approximately 631,743 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 725,458 shares. The stock had previously closed at $0.41.

Several analysts recently commented on ATNM shares. B. Riley set a $3.00 price objective on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, February 16th. Zacks Investment Research downgraded shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 15th. Finally, Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, December 6th. Five investment analysts have rated the stock with a buy rating, Actinium Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $3.75.

The company has a market cap of $32.44, a price-to-earnings ratio of -0.89 and a beta of 40.64.

A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. D.A. Davidson & CO. raised its holdings in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 227.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 157,000 shares of the biotechnology company’s stock after acquiring an additional 109,000 shares during the quarter. D.A. Davidson & CO. owned approximately 0.20% of Actinium Pharmaceuticals worth $104,000 as of its most recent filing with the Securities and Exchange Commission.

TRADEMARK VIOLATION WARNING: This report was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply